Go to Page # Page of 32
loading

Drug Candidates Targeting the DNA Damage Response (DDR)

 Sierra Oncology, Inc.
  19th-Apr-2019
Description: Sierra is advancing two drug candidates targeting the DNA Damage Response. Cdc7 is a next-generation DDR target for cancer, with a key role in controlling the initiation of DNA replication.
Views: 2305
Domain: Medical
Category: Biotech/Pharma
Contributing Organization: Sierra Oncology, Inc.
 ‐ More of their Presentations
Contents:
Charting the path from
pioneering biology to
impactful therapeutics
AACR 2019 Late-Breaking Data for
SRA141 targeting Cdc7

NASDAQ: SRRA

S A F E H A R B O R S TAT E M E N T
Except for statements of historical fact, any information contained in this presentation may be a forward-looking
statement that reflects the Company’s current views about future events and are subject to risks, uncerta ... See more

Recent Presentations

Regulatory Science for R&D Promotion

At present, the nationís policy for Research and Development (R&D) promotion of innovative pharmaceuticals & improvement of environments for the R&D is formulated by Japanese gover

...
18 August, 2019
...
16 August, 2019

Stewards of High-Value Imaging

This project helped strengthen the relationship between the radiologists and ED physicians and set the stage for increased collaboration over time.

...
15 August, 2019